Earnings call transcript: Core Laboratories misses Q3 2025 earnings expectations

Core Laboratories NV (CLB) reported its third-quarter earnings for 2025, revealing a significant miss in both earnings per share (EPS) and revenue compared to market forecasts. The company’s EPS came in at $0.22, falling short of the expected $0.35, marking a 37.14% negative surprise. Revenue was also below expectations at $134.5 million, compared to the forecasted $160.5 million, a shortfall of 16.2%. Despite these misses, the stock saw a notable premarket increase of 16.6%, closing at $14.89. According to InvestingPro analysis, CLB currently appears undervalued, with a "GOOD" overall financial health score of 2.52 out of 5.

[Get access to 7 more exclusive InvestingPro Tips for CLB and over 1,400 other stocks with an InvestingPro subscription.]

Key Takeaways

• Core Laboratories reported a 37.14% negative surprise in EPS for Q3 2025.
• Revenue was flat year-over-year but increased 3% sequentially.
• Stock price surged 16.6% in premarket trading following the earnings release.
• The company completed phase one of a major reservoir fluid study in the Middle East.
• Net debt was reduced to $91.4 million, with an improved leverage ratio of 1.1.

Company Performance

Core Laboratories experienced a challenging quarter with its financial performance not meeting market expectations. Revenue for Q3 2025 was $134.5 million, which was flat compared to the same period last year but showed a 3% sequential increase. The company highlighted growth in its service revenue, which rose 5% sequentially and 2% year-over-year, while product sales declined slightly both quarter-over-quarter and year-over-year. The company maintains strong liquidity with a current ratio of 2.27, and operates with a moderate debt-to-equity ratio of 0.68, according to recent InvestingPro data.

Financial Highlights

• Revenue: $134.5 million (flat year-over-year, up 3% sequentially)
• Service Revenue: $101.1 million (up 5% sequentially, up 2% year-over-year)
• Product Sales: $33.4 million (down slightly quarter-over-quarter, down 6% year-over-year)
• Net Income (ex items): $10.2 million (up 15% sequentially, down 14% year-over-year)
• Earnings per share (ex items): $0.22 (up from $0.19 last quarter, down from $0.25 last year)

Earnings vs. Forecast

Core Laboratories posted a significant earnings miss for Q3 2025, with EPS at $0.22 compared to the forecasted $0.35, resulting in a 37.14% negative surprise. Revenue also fell short at $134.5 million against the expected $160.5 million, a 16.2% miss. This marks a notable deviation from the company’s historical performance, where it has often met or exceeded market expectations.

Market Reaction

Following the earnings announcement, Core Laboratories’ stock experienced a substantial increase in premarket trading, rising 16.6% to $14.89. This movement suggests that investors may be focusing on the company’s operational improvements and strategic initiatives rather than the earnings miss. The stock’s current price is still below its 52-week high of $21.83 but significantly above its 52-week low of $9.72. With a beta of 1.38, the stock shows higher volatility than the broader market, while maintaining an impressive 18-year track record of consistent dividend payments.

Outlook & Guidance

For Q4 2025, Core Laboratories projects revenue between $132 million and $136 million and operating income of $14 million to $16.1 million. The expected EPS for the next quarter is between $0.18 and $0.22. The company remains optimistic about its international market presence, particularly in the Middle East and South Atlantic margin. InvestingPro data shows analyst price targets ranging from $10 to $18, with a consensus recommendation of "Hold."

[Discover comprehensive analysis and detailed financial metrics in the Pro Research Report, available exclusively with an InvestingPro subscription.]

Executive Commentary

CEO Larry Bruno emphasized the company’s unique positioning in reservoir optimization technologies and its strong international market presence. He stated, "We have never been better operationally or technologically positioned to help our global client base optimize their reservoirs." Bruno also highlighted the ongoing need for investment in oil and gas resource development, particularly in non-OECD countries.

Risks and Challenges

• Potential for continued volatility in oil prices affecting demand for services.
• Ongoing global economic uncertainties impacting investment in oil and gas exploration.
• Competitive pressures in the reservoir optimization and diagnostic services market.
• Risks associated with geopolitical tensions in key international markets.
• Challenges in maintaining operational efficiency amid fluctuating market conditions.

Q&A

During the earnings call, analysts inquired about the Solantec acquisition, which features a unique earnout structure. Executives expressed a positive outlook on global activity levels and anticipated increased investment in international exploration and development. The company remains focused on leveraging its technological advancements to drive future growth.

Full transcript - Core Laboratories NV (CLB) Q3 2025:

Danielle, Conference Operator: Today, and welcome to the Core Laboratories Inc. Q3 2025 earnings call. All participants will be in the listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today’s presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Larry Bruno, Chairman and CEO. Please go ahead.

Larry Bruno, Chairman and CEO, Core Laboratories Inc.: Thanks, Danielle. Good morning in the Americas, good afternoon in Europe, Africa, and the Middle East, and good evening in Asia Pacific. We’d like to welcome all of our shareholders, analysts, and most importantly, our employees to Core Laboratories Inc.’s third quarter 2025 earnings call. This morning, I’m joined by Chris Hill, Core’s Chief Financial Officer, and Gwen Gresham, Core’s Senior Vice President and Head of Investor Relations. The call will be divided into six segments. Gwen will start by making remarks regarding forward-looking statements. We’ll then have some opening comments, including a high-level review of important factors in Core’s Q3 performance. In addition, we’ll review Core’s strategies and the three financial tenets that Core employs to build long-term shareholder value. Chris will then give a detailed financial overview and have additional comments regarding shareholder value. Following Chris, Gwen will provide some comments on the company’s outlook and guidance.

I’ll then review Core’s two operating segments, detailing our progress and discussing the continued successful introduction and deployment of Core Labs Technologies, as well as highlighting some of Core’s operations, recent client interactions, and major projects worldwide. We will open the phones for a Q&A session. I’ll now turn the call over to Gwen for remarks on forward-looking statements.

Danielle, Conference Operator: Before we start the conference this morning, I’ll mention that some of the statements that we make during this call may include projections, estimates, and other forward-looking information. This would include any discussion of the company’s business outlook. These types of forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to materially differ from our forward-looking statements. These risks and uncertainties are discussed in our most recent annual report on Form 10-K, as well as other reports and registration statements filed by us with the SEC. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Our comments also include non-GAAP financial measures. Reconciliation to the most directly comparable GAAP financial measures is included in the press release announcing our third quarter results.

Those non-GAAP measures can also be found on our website. With that said, I’ll pass the discussion back to Larry.

Larry Bruno, Chairman and CEO, Core Laboratories Inc.: Thanks, Gwen. Moving now to some high-level comments about our third quarter 2025 results. Core continued to execute its strategic plan of technology investments targeted to both solve client problems and capitalize on Core’s technical and geographic opportunities. Third quarter 2025 revenue was up over 3% compared to Q2, and Core achieved nice sequential improvement in operating income, operating margins, and earnings per share. Looking at reservoir description in more detail, revenue in the third quarter was up over 2% compared to Q2. For the third quarter, excluding items, operating margins in reservoir description were 13%. The segment’s financial performance in the third quarter reflects continued demand for rock and fluid analysis across the company’s global laboratory network. Demand for laboratory services tied to the assay of crude oil and derived products remained steady as trading patterns somewhat improved following disruptions caused by sanctions.

There is still uncertainty in the demand for these assay services due to ongoing international geopolitical conflicts and evolving sanctions. In addition, pending tariffs and supply-demand balance concerns continue to generate volatility in commodity prices. In production enhancement, third quarter revenue was up 6% compared to Q2. Excluding items, third quarter 2025 operating margins were 11%, up from 9% in Q2. This sequential improvement in margins reflects continued demand for completion diagnostic services, both onshore and offshore, along with improved international product sales. In addition to our quarterly dividend, CoreLab returned excess free cash to our shareholders by repurchasing more than 462,000 shares of company stock during the third quarter, equating to approximately 1% of Core’s outstanding share count and representing a value of $5 million. Looking forward, Core intends to use free cash to fund our quarterly dividend, pursue growth opportunities, and improve shareholder value through opportunistic share repurchases.

As we look ahead, Core will continue to execute on its key strategic objectives by, one, introducing new product and service offerings in key geographic markets, two, maintaining a lean and focused organization, and three, maintaining our commitments to returning excess free cash to our shareholders and strengthening the company’s balance sheet. Now to review Core Laboratories Inc.’s strategies and the financial tenets that the company has used to build shareholder value over our nearly 30-year history as a publicly traded company. The interests of our shareholders, clients, and employees will always be well served by Core Laboratories Inc.’s resilient culture, which relies on innovation, leveraging technology to solve problems, and dedicated customer service. I’ll talk more about some of our latest innovations in the operational review section of this call.

While we continue to pursue growth opportunities, the company will remain focused on its three longstanding long-term financial tenets, those being to maximize free cash flow, maximize return on invested capital, and returning excess free cash to our shareholders. I’ll now turn it over to Chris Hill for the detailed financial review. Thanks, Larry Bruno. Before we review the financial performance for the quarter, the guidance we gave on our last call and past calls specifically excluded the impact of any FX gains or losses and assumed an effective tax rate of 25%. Accordingly, our discussion today excludes any foreign exchange gain or loss for current and prior periods. Additionally, adjustments which net to a gain of $4.6 million have been excluded from today’s discussion of the third quarter 2025 financial results.

You can find a summary of those items in the tables attached to our press release for the third quarter of 2025. Now, looking at the income statement, revenue was $134.5 million in the third quarter, up $4.4 million or over 3% compared to the prior quarter and flat year over year. The sequential improvement is primarily associated with increased demand for our laboratory assay services and completion diagnostic services in international regions. Of this revenue, service revenue, which is more international, was $101.1 million for the quarter, up 5% sequentially and up over 2% year over year. As mentioned early, sequentially we saw an increase in international service revenue for both our laboratory assay services and our completion diagnostic services when compared to the second quarter. For the U.S., service revenue remained flat sequentially and was down almost 4% from last year.

Product sales, which was more equally tied to North America and international activity, were $33.4 million for the quarter, down slightly from last quarter and down 6% year over year. Our international product sales are typically larger bulk orders and can vary from one quarter to another, and were up nicely in the third quarter when compared to the second quarter. However, laboratory instrumentation sales decreased in the third quarter, but coming off a very strong second quarter. Looking at year over year, the decrease in product sales was primarily due to the lower levels of completion activity in the U.S. onshore market. Moving on to cost of services, X items for the quarter was 74% of service revenue, improving from 77% in the prior quarter and from 76% in the same quarter last year.

The year over year and sequential improvements in cost of services were primarily due to cost efficiencies and reductions in overall compensation costs associated with actions taken earlier this year. Cost of sales X items in the third quarter was 88% of revenue compared to 85% last quarter and flat compared to last year. The sequential increase was due to higher absorption of fixed costs on a slightly lower revenue base in the quarter, as well as an increase in the cost of imported steel due to tariffs. As we continue to focus on cost efficiencies, we anticipate the manufacturing absorption rate in future quarters will be in line with projected product sales. G&A X items for the quarter was $10.7 million, a slight increase from $10.5 million in the prior quarter and $10 million in the same quarter of the prior year.

For 2025, we expect G&A X items to be approximately $42 to $44 million. Depreciation and amortization for the quarter was $3.6 million, decreased slightly compared to $3.7 million in the last quarter and the same quarter in the prior year. EBIT X items for the quarter was $16.6 million, up $2.1 million from $14.5 million last quarter, yielding an EBIT margin over 12% and expanding 120 basis points sequentially. Our EBIT for the quarter on a GAAP basis was $20.9 million, which includes a gain of approximately $5.2 million associated with the final settlement of insurance claim for our UK facility that was damaged by fire. Interest expense of $2.7 million remained flat compared to the prior quarter and decreased from $3.1 million last year. The decrease in interest expense from last year is due to a lower average borrowings on the credit facility in 2025.

Income tax expense at an effective rate of 25% and X items was $3.5 million for the quarter. On a GAAP basis, we recorded tax expense of $3.8 million for the quarter at an effective rate of 21%. The effective tax rate will continue to be somewhat sensitive to the geographic mix of earnings across the globe and the impact of items discrete to each quarter. We continue to project the company’s effective tax rate to be approximately 25% for 2025. Net income ex items for the quarter was $10.2 million, an increase of over 15% sequentially, but down almost 14% from the same quarter last year. On a GAAP basis, we had net income of $14.2 million for the quarter. Earnings per diluted share ex items was $0.22 for the quarter, an increase from $0.19 in the prior quarter and a decrease from $0.25 last year.

On a GAAP basis, EPS was $0.30 for the third quarter of 2025. Turning to the balance sheet, receivables were $110.3 million and decreased approximately $3.6 million from the prior quarter. Our DSOs for the third quarter improved to 71 days from 75 days last quarter. Inventory at September 30, 2025 was $58.2 million, down $1.5 million from last quarter end. Inventory turns for the quarter improved to 2.0, up from 1.9 in the prior quarter. We continue to focus on managing our inventory to lower levels with improved returns and anticipate inventory turns will gradually improve over time. Now to the liability side of the balance sheet. Our long-term debt was $117 million as of September 30, 2025, and considering cash of $25.6 million, net debt was $91.4 million, which decreased $3.4 million from last quarter.

Our leverage ratio was reduced to 1.1 at September 30, down from 1.27 last quarter end. As of September 30, 2025, our debt was comprised of $110 million in senior notes and $7 million outstanding under our bank credit facility. As Larry Bruno stated earlier, the company will remain focused on executing its strategic business initiatives while maintaining a healthy balance sheet. Looking at cash flow for the third quarter of 2025, cash flow from operating activities was approximately $8.5 million, and after paying $2 million of CapEx for operations, our free cash flow for the quarter was $6.5 million. As discussed in prior quarters, the capital expenditures associated with rebuilding our UK facility, which was damaged by fire in February 2024, are covered by the company’s property and casualty insurance and have been excluded in the calculation of free cash flow.

Additionally, we expect CapEx to remain aligned with activity levels, and for the full year 2025, we expect capital expenditures for operations to be in the range of $11 million to $13 million. The forecast for capital expenditures excludes CapEx associated with rebuilding the UK facility. Core Laboratories Inc. will continue its strict capital discipline and asset-light business model with capital expenditures primarily targeted at growth opportunities. Core Laboratories Inc.’s operational leverage continues to provide the ability to grow revenue and profitability with minimal capital requirements. Capital expenditures have historically ranged from 2.5% to 4% of revenue, even during periods of significant growth. That same level of laboratory infrastructure, intellectual property, and leverage exists in the business today.

We believe evaluating a company’s ability to generate free cash flow and free cash flow yield is an important metric for shareholders when comparing and projecting companies’ financial results, particularly for those shareholders who utilize discounted cash flow models to assess valuations. I will now turn it over to Gwen Gresham for an update on our guidance and outlook.

Danielle, Conference Operator: Thank you, Chris. Turning to Core Laboratories Inc.’s outlook for the fourth quarter, the IEA, the EIA, and OPEC+ continue to forecast growth in crude oil demand between 700,000 and 1.3 million barrels per day in 2025, with a similar level of incremental growth projected for 2026. This growth continues to be driven primarily by demand from non-OECD countries, including Asia, India, and emerging markets across the Middle East and Africa. As noted in the IEA’s report published September 16, 2025, crude oil field data shows the natural decline in existing producing fields is accelerating globally and now represents a major long-term supply risk. Addressing steeper decline rates and bringing new fields online will be central to ensuring energy security and maintaining market stability. As such, according to the IEA, significant annual investment in oil and gas resource development will be required for many years to come.

Core Laboratories Inc.’s reservoir description and production enhancement technologies are directly aligned with these investment imperatives. In the near term, potential tariff headwinds, combined with OPEC+ decisions to increase production levels, are contributing to market volatility and lower commodity prices. Despite the current softness in long-term crude oil demand, fundamentals remain intact. Core Laboratories Inc. maintains its constructive outlook and continues to see steady activity across committed long-cycle projects, including deepwater along the South Atlantic margin, North and West Africa, Norway, the Middle East, and certain areas of Asia Pacific. These projects, by nature of their scale and planning cycles, tend to be less reactive to near-term commodity price fluctuations. Core Laboratories Inc.’s revenue opportunity on awarded projects will remain somewhat dependent on our clients’ geological success rates. Activity tied to smaller scale short-cycle crude oil development projects is expected to remain more sensitive to changes in commodity prices.

As a result, changes in crude oil prices are anticipated to have a more immediate impact on drilling and completion activity in the U.S. onshore market. Geopolitical conflicts, evolving trade and tariff dynamics, and volatile commodity prices continue to create uncertainty in demand for laboratory services tied to the maritime transportation and trade of crude oil and derived products. Despite these headwinds, Core Laboratories Inc. projects reservoir description’s fourth quarter revenue to be up sequentially. The U.S. BRAC spread count continues to trend lower, and the company anticipates the typical year-end seasonal decline in U.S. onshore completion activity. However, growth in demand for Core’s diagnostic services and energetic system product sales in both international and offshore markets may somewhat offset the decline in U.S. onshore activity. As such, Core projects production enhancement to be down slightly sequentially.

Core believes that the tariff measures under consideration will not apply to the vast majority of service revenue and product sales provided by the company. Core’s services account for over 75% of the company’s total revenue and are currently not subject to tariffs. Core’s product sales have been less than 25% of total revenue and are primarily manufactured in the U.S. Tariffs on exported products would not apply to approximately 50% of these product sales, as they are consumed in the U.S. drilling and completion market. Certain raw materials imported and consumed in production enhancements, U.S. product manufacturing, and service businesses are attracting import tariffs. We continue to take steps to mitigate the impact of tariffs. In summary, reservoir description’s fourth quarter revenue is projected to range from $88 million to $90 million, with operating income of $11 million to $12.3 million.

Production enhancement’s fourth quarter revenue is estimated to range from $44 million to $46 million, with operating income of $2.9 million to $3.7 million. Core’s fourth quarter 2025 revenue is projected to range from $132 million to $136 million, with operating income of $14 million to $16.1 million, yielding operating margins of approximately 11%. EPS for the fourth quarter is expected to range from $0.18 to $0.22. The company’s fourth quarter 2025 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. Our fourth quarter guidance assumes an effective tax rate of 25%. With that, I’ll turn it back over to Larry.

Larry Bruno, Chairman and CEO, Core Laboratories Inc.: Thanks, Gwen. First, I’d like to thank our global team of employees for providing innovative solutions, integrity, and superior service to our clients. The team’s collective dedication to servicing our clients is the foundation of Core Laboratories Inc.’s success. Looking at the macro, as Gwen mentioned, even after assessing current and near-term economic headwinds, the IEA, EIA, and OPEC+ projections continue to point to growth in global crude oil demand in 2025 and beyond. The various estimates show growth in demand of between 0.7 and 1.3 million barrels per day for 2025, with similar additional demand growth projected for 2026. In addition to the forecasted growth in demand, new production will need to be brought online to offset the natural decline from existing producing fields. Combined, these trends will require continued investment in the development of onshore and offshore crude oil fields. U.S.

tight oil production has been by far the largest component of non-OPEC oil production growth since 2010. Continued growth in global oil demand, combined with constrained incremental U.S. oil production growth, supports the thesis that the balance of future supply growth must increasingly rely on discoveries and field developments outside the U.S. In summary, the current forecast suggests a multi-year cycle in which U.S. onshore production growth slows and future growth in global supply will be driven by capital investment in international conventional offshore fields and unconventional opportunities in the Middle East. These trends support increased demand for Core Laboratories Inc. services across the globe, particularly for reservoir description. The most recent EIA short-term energy outlook for U.S. oil production is 13.5 million barrels per day in 2025, and the agency currently projects production to remain essentially flat in 2026, with only nominal growth in U.S. production over this timeframe.

Of particular note, during the third quarter, the IEA pivoted from earlier projections on the need for investment in new oil and gas production, stating that in addition to continued investment in existing fields, more than 45 million barrels of oil production from new conventional oil fields must be added by 2050 just to maintain current production levels. Any growth in demand would add to that number. The IEA now states that significant annual investment in oil and gas resource development will be required for many years to come as the natural decline in existing producing fields is accelerating globally. The new IEA analysis published in September, the agency’s global field-by-field data show that steeper natural declines now dominate supply risk. The IEA quantified this risk, stating that oil output would fall approximately 8% per year from natural decline.

Nearly 90% of upstream CapEx since 2019 has gone just to offset declines, not to meet continuing demand growth. Additionally, the IEA sees 20-year average project lead times, and they conclude that delayed or inefficient development of new production will further compound this supply risk. Directionally, these IEA revisions in the need for increased investment in oil and gas projects align with Core Laboratories Inc.’s longstanding view that the decline curve never sleeps and always wins. Along with new exploration, appraisal, and development programs, disciplined data-driven optimization of existing reservoirs is the fastest, lowest-risk path to supply reliability and operator returns, a scenario that Core Laboratories Inc.

is uniquely positioned to deliver through its reservoir description and production enhancement technologies. With Core Laboratories Inc.’s expanding opportunities across international markets, such as with unconventional plays in the Middle East and emerging onshore and offshore deep work conventional plays in a number of regions, including along the South Atlantic margin, the company continues to enhance its portfolio of innovative offerings for our growing global client base. Now let’s review the third quarter performance of our two business segments. Turning first to reservoir description. For the third quarter of 2025, revenue came in at $88.2 million, up over 2% compared to Q2. For Q3, operating income for reservoir description, ex items was $11.6 million, up from $10.8 million in Q2, yielding operating margins of 13% with incremental margins of 41%.

While demand for reservoir description laboratory services remains strong in several regions across our global network, ongoing international geopolitical conflicts, along with sanctions, continue to produce headwinds that impact the demand for laboratory services tied to the trade and transportation of crude oil and derived products. The demand for these services did rebound some in the third quarter as trading patterns continue to realign. Now for some operational highlights from reservoir description. In the third quarter of 2025, Core Laboratories Inc. completed phase one of a major reservoir fluid study in the Middle East. This analytical program addressed the critical challenge of crude oil stability by determining how natural pressure depletion impacts asphaltene behavior. As pressure drops across producing reservoirs, asphaltenes can precipitate from some crude oils. These solid particles can then clog pore throats, impair permeability, and even obstruct production tubulars.

Consequently, asphaltene precipitation has significant implications for both production efficiency and infrastructure integrity. As reservoirs mature, a decline in pressure will destabilize the delicate balance of pressure, volume, and temperature, or PVT, that governs the thermodynamic behavior of the crude oil. This disruption can cause costly formation damage in the subsurface, leading to reduced production rates and other operational issues. The operator engaged Core Laboratories Inc. to deploy its proprietary full visualization PVT laboratory technologies alongside Core’s advanced near-infrared and high-pressure microscopy detection techniques. Combined, these technologies enabled precise measurement of asphaltene onset pressures and depositional behaviors under a range of reservoir and production conditions. Concurrently, Core Laboratories Inc. designed and executed advanced laboratory core flood experiments to quantify permeability impairment as the laboratory system pressure was reduced to below critical asphaltene precipitation thresholds.

These laboratory results form the essential hard data inputs into dynamic reservoir models that will allow the client to mitigate risk as they develop pressure maintenance strategies for the field. This project is now progressing into phase two, which will assess the feasibility of pressure maintenance and solvent injection programs aimed at permeability restoration and reducing formation damage. Throughout the life cycle of oil fields, Core Laboratories Inc.’s measurements and interpretations help our clients maximize hydrocarbon production from their assets. Moving now to production enhancement, where Core Laboratories Inc.’s technologies continue to help our clients maximize their well completions and improve production. Revenue for production enhancement for Q3 came in at $46.3 million, up 6% compared to Q2. Third quarter operating income for production enhancement, excluding items, was $4.9 million, yielding operating margins of 11%, up from 9% in Q2.

In the U.S., diagnostic services benefited from increasing demand as complex U.S. land completion designs like trimal fracks and extended lateral length horizontal wells become more and more common. Core’s expansive portfolio of completion products also saw increased demand in international markets. Now for some operational highlights from production enhancement. In the third quarter of 2025, a national oil company engaged Core Laboratories Inc.’s production enhancement team after experiencing nearly two months of costly downtime due to a stuck heavyweight drill pipe in a well from offshore West Africa. The operator deployed Core’s proprietary dual-end severing tool, which is engineered for high-efficiency pipe recovery operations, particularly in scenarios where conventional drill pipe and casing cutters are not up to the task. Core Laboratories Inc.

provided the operator with extensive assembly and field application procedures and training and real-time guidance to determine the optimal deployment position within the wellbore for maximum effectiveness. Core’s proprietary tool works by using precisely timed energetic events that are sequenced to generate two equal and opposing shock fronts. This technology focuses the energy outward toward the drill string and severs the drill collar. As a result of Core Laboratories Inc.’s proprietary technologies and unmatched client service, the drill pipe was successfully recovered and well operations were restored. Also in the third quarter, one of Canada’s most active heavy oil operators needed to identify which boreholes in the multilateral wells were contributing the most oil to overall production. This is a key challenge in optimizing completions in low-temperature heavy oil reservoirs.

Having successfully used Core Laboratories Inc.’s SpectraChem water tracers in previous multi-stage fracturing operations, the operator again turned to Core’s engineering team for a solution using chemical tracers to assess oil production from these challenging, complex wells. The operator deployed Core’s unique flow profiler engineer delivery system, or EDS. These oil tracers were placed into each lateral leg, allowing the operator to monitor produced oil concentrations and generate a precise production contribution profile. The operator found the diagnostic results to be of high value and is now including Core Laboratories Inc.’s flow profiler EDS oil tracers as a standard evaluation technology for future projects. That concludes our operational review. We appreciate your participation, and Danielle will now open the call for questions.

Danielle, Conference Operator: Thank you. We will now begin the question and answer session. To ask a question, you may press star, then one on your touch-tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star, then two. The first question comes from John Daniel from Daniel Energy Partners. Please go ahead.

Larry Bruno, Chairman and CEO, Core Laboratories Inc.: Yeah, morning, John.

Good morning. Hopefully, you can hear me okay.

Yep.

The first question is on the transaction you all just did. If you could elaborate on maybe what some of the opportunities might be for similar-sized transactions globally. This is a sidebar comment. I thought it was an interesting way you structured the purchase price where a lot of it’s on the back end in terms of an earnout. It’s a pretty neat way to do that. Just any color on those opportunities.

I’ll let Chris fill in a lot of the details on that. Just a little background there, John. I think you know I came to CoreLab now, 26 or so years ago through a similar sort of tuck-in technology acquisition, and I have a pretty good model for that. CoreLab did a series of those private company acquisitions. They offer technological advantages. They offer geographic advantages. As you and some of the other folks have heard us say before, everybody’s got hockey stick projections on how their business is going to play out over the next few years. We think it’s a good approach to have them participate in that, the need to deliver that hockey stick, if they’re going to be rewarded for that hockey stick. I think that approach makes sense. I think we’re always looking at similar acquisitions.

Chris, any color you might want to add on the Solantec acquisition?

I think the way we did structure that may be a little unique from what you normally see. We would love to structure, you know, most transactions like that, but it takes, you know, two parties to agree on what those terms look like. We are very happy with the acquisition, and then it’s kind of a win-win if we end up paying that earnout for both the seller and us.

I would add to that that Solantec has a long multi-decade history in Brazil, and we are really glad to have them part of the CoreLab family.

Thank you. I guess this is my follow-up question, a bit unrelated to the M&A market. You guys do a really good job of kind of traveling the globe and seeing your customers. I think you alluded to going to Asia Pac in the third quarter. I’m curious, when you sit down and talk with those folks, obviously without naming names, when they look into their crystal ball two to three to four years from now, are they suggesting to you higher activity, lower activity? Any color would be appreciated.

Yeah, higher activity. It’s across the board. I’d say it’s Middle East still leading the pack. South Atlantic margin and West Africa, I would say, are in the second position. Recently here in Asia Pac, we’re seeing some, sort of, I’ll call it, they’ve been on the drawing board for a while, but finally getting closer to getting kinetic, if you will, on some exploration programs. With those, for us, there’s some work tied to exploration, but we really hope our clients are geologically successful, because it’s when they get into appraisal and development, that’s really kind of the wheelhouse, particularly for reservoir description, and then eventually into production. That plays out into our production enhancement group. It’s clearly rising in our perspective here that activity levels over the next few years should be going up.

I think we have even more confidence into the trends that we’ve been describing over the last year or so, saying that, hey, there is a wave coming of more international investment. I think it’s tied to a realization that the production from U.S. land has largely absolved the rest of the world from having to bring new production on. That phase, that 15-year cycle from 2010 to 2025, look, there’s still going to be a lot of oil and gas produced in the U.S., but the growth that has covered a lot of the decline around the rest of the world, that’s starting to come to an end.

Okay, that’s very helpful. Thank you for including me.

Yeah, thanks, John. Appreciate the call.

Danielle, Conference Operator: As a reminder, if you have a question, please press star one. Seeing that there are no further questions, I would like to turn the conference back over to Larry Bruno for closing remarks.

Larry Bruno, Chairman and CEO, Core Laboratories Inc.: Okay, thanks, Danielle. We’ll wrap up here. I think we’ve got a pretty busy earnings release morning going on here, so probably a little bit of people juggling phones. In summary, Core’s operational leadership continues to position the company for improving client activity levels in the coming quarters and years. We have never been better operationally or technologically positioned to help our global client base optimize their reservoirs and to address their evolving needs. We remain uniquely focused and are the most technologically advanced, client-focused reservoir optimization company in the oilfield service sector. The company will remain focused on maximizing free cash and returns on invested capital. In addition to our quarterly dividend, we’ll bring value to our shareholders via growth opportunities driven by both the introduction of problem-solving technologies and new market penetration.

In the near term, Core will continue to use free cash to repurchase shares and strengthen its balance sheet while always investing in growth opportunities and evaluating various methods to increase shareholder value. In closing, we thank and appreciate all of our shareholders and the analysts that cover CoreLab. The executive management team and the board of Core Laboratories give a special thanks to our worldwide employees that have made these results possible. We’re proud to be associated with their continuing achievements. Thanks for spending time with us, and we look forward to our next update. Goodbye for now.

Danielle, Conference Operator: The conference is now concluded. Thank you for attending today’s presentation. You may now disconnect.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.